Jpmorgan Chase & CO Global Blood Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$32.4 - $68.18 $61.5 Million - $129 Million	1,898,523 Added 467.49%	2,304,636 $157 Million
Q2 2022 Aug 11, 2022	BUY	$22.3 - $37.39 $4.93 Million - $8.26 Million	220,883 Added 119.25%	406,113 $13 Million
Q1 2022 May 11, 2022	BUY	$25.68 - $35.59 $379,396 - $525,806	14,774 Added 8.67%	185,230 $6.42 Million
Q4 2021 Feb 10, 2022	BUY	$24.9 - $40.26 $2.93 Million - $4.74 Million	117,734 Added 223.31%	170,456 $4.99 Million
Q3 2021 Nov 12, 2021	BUY	$25.48 - $37.34 $1.34 Million - $1.97 Million	52,722 New	52,722 $1.34 Million

288K

Ticker GBT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,476,200
Market Cap $4.62B
Description
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.